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Abstract
Tumorigenesis is a multi-step process in which normal cells transform into malignant tumors following the accumulation of
genetic mutations that enable them to evade the growth control checkpoints that would normally suppress their growth or
result in apoptosis. It is therefore important to identify those combinations of mutations that collaborate in cancer
development and progression. DNA copy number alterations (CNAs) are one of the ways in which cancer genes are
deregulated in tumor cells. We hypothesized that synergistic interactions between cancer genes might be identified by
looking for regions of co-occurring gain and/or loss. To this end we developed a scoring framework to separate truly co-
occurring aberrations from passenger mutations and dominant single signals present in the data. The resulting regions of
high co-occurrence can be investigated for between-region functional interactions. Analysis of high-resolution DNA copy
number data from a panel of 95 hematological tumor cell lines correctly identified co-occurring recombinations at the T-cell
receptor and immunoglobulin loci in T- and B-cell malignancies, respectively, showing that we can recover truly co-
occurring genomic alterations. In addition, our analysis revealed networks of co-occurring genomic losses and gains that are
enriched for cancer genes. These networks are also highly enriched for functional relationships between genes. We further
examine sub-networks of these networks, core networks, which contain many known cancer genes. The core network for
co-occurring DNA losses we find seems to be independent of the canonical cancer genes within the network. Our findings
suggest that large-scale, low-intensity copy number alterations may be an important feature of cancer development or
maintenance by affecting gene dosage of a large interconnected network of functionally related genes.
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Introduction
Tumor development is generally thought to be a process in
which healthy cells transform into malignant tumor cells through
the step-wise acquisition of oncogenic alterations [1,2]. This
implies that certain changes have to occur together for effective
oncogenic transformation of a normal cell. There are a multitude
of (epi-)genetic lesions that cause deregulated expression of
oncogenes and tumor suppressor genes. Co-operative deregulation
of cancer genes has indeed been observed in several different
settings. Retroviral insertional mutagenesis screens in mice have
shown preferential co-mutation of specific combinations of genes
within the same tumor [3]. Likewise, in a study where a thousand
individual tumors were screened for mutations in 17 different
oncogenes, preferential co-mutation of the PIK3CA and KRAS
genes was observed [4].
Besides single basepair mutations or retroviral integrations, the
activity of genes can also be perturbed by DNA copy number
alterations that arise as a result of genomic instability, which is
frequently observed in tumor cells [1]. Whether genomic
instability is important for tumor initiation is controversial, but
its contribution to tumor progression is undisputed [5,6]. Loss of
DNA is a mechanism for the tumor to eliminate copies of tumor
suppressor genes, which prevent cancer formation. Conversely,
DNA copy number gain or amplification may lead to activation of
oncogenes that promote tumor development. We aimed to find
genomic regions of gains and losses that are preferentially gained
or lost together. We could subsequently link genes that lie in co-
occurring regions to each other, allowing us to find functional
interactions that reveal the mechanisms underlying tumor
development.
DNA copy number alterations (CNAs) may be measured on
microarray platforms [7]. Array-based comparative genomic
hybridization (aCGH) of differentially labeled tumor and normal
(2n) DNA is performed on oligonucleotide- or Bacterial Artificial
Chromosome (BAC) based microarray platforms. For each probe
on the microarray, the ratio of signal intensities of tumor versus
normal DNA is a measure of the relative DNA copy number of the
PLoS Computational Biology | www.ploscompbiol.org 1 January 2010 | Volume 6 | Issue 1 | e1000631corresponding genomic region in the tumor sample. Platforms
designed to identify single nucleotide polymorphisms (SNPs) can
also infer CNAs by comparing the raw probe intensity values
measured in a tumor sample with a reference sample.
In order to extract those DNA copy number aberrations that
preferentially occur together, we developed an analysis framework.
The basic premise of our analysis is to define a pair-wise score for
any given pair of genomic locations present in the dataset. This
scoring index will only be high if both genomic locations are
recurrently aberrated in multiple independent samples within the
tumor panel, and if they co-vary similarly over the different
samples (Figure 1). Using a Gaussian kernel convolution method
we look for aggregates of high scores in the 2D genomic pair-wise
space (Figure 2). The top peaks in the convolved score matrix can
be mapped back to two distinct co-mutated genomic locations.
The genes that reside in these genomic locations can then be
functionally related to each other.
The raw data consist of non-discrete measurements of the
average DNA copy number of the population of cells present in
the measured sample. The signal consists of a measurement of a
heterogeneous population of tumor cells, which may contain many
populations potentially carrying different mutations and copy
number alterations, as well as normal (diploid) cells. To reduce
heterogeneity as much as possible we choose to analyze a
collection of hematopoietic tumor cell lines, which on a per-
sample basis can be considered clonal. There were several other
reasons for analyzing this particular dataset. First, it is a high
resolution dataset of well-characterized, clinically relevant samples.
Although these samples are cell lines, they are widely used as a
model system for the diseases from which they have been derived.
Second, this collection of samples includes cell lines derived from
T- and B-cell leukemias carrying rearranged T-cell receptor and
immunoglobulin loci, respectively. We therefore should be able to
separate these two distinct lymphoid malignancies based on co-
occurring DNA copy number losses at the T-cell receptor and
immunoglobulin loci. During T- and B-cell development, these
loci undergo DNA recombination and gene deletion in a process
known as V(D)J-recombination. The human genome contains
three specific T-cell receptor loci (alpha/delta, beta and gamma)
on two different chromosomes that determine their variability. B-
cells have three different loci (IgG kappa, IgG lambda and the IgG
heavy chain) on three different chromosomes that undergo
recombination to generate a diverse repertoire of immunoglobu-
lins. Since T- and B-cells only undergo recombination of their
respective loci after lineage commitment, it is unlikely that T-cell
receptor loci are recombined in B-cells and vice-versa. If our
approach is successful at finding co-occurring losses, it should
identify the co-occurring rearrangements at the T-cell receptor
alpha/delta and beta/gamma loci in T-cell leukemias. Similarly,
we should be able to pick up co-occurring losses at the IgG kappa,
lambda and heavy chain loci in B-cell malignancies.
Results
Defining a continuous co-occurrence score
A classic example of finding associations in a large (binary)
dataset is association rule mining. Identification of cooperating
events in continuous data requires a different approach than
binary association rule mining. First we developed a method to
score for co-occurrence between two continuous measurements
(Figure 1). We then applied this score in a framework that is able
to find co-occurrences in genome-wide measurements. This
framework is shown in Figure 2 and is detailed in the Materials
and Methods.
DNA copy number measurements at two different genomic loci
can be visualized in a 2D space, with each axis representing
measurements at a certain genomic locus. A point in this space
represents a sample in which both loci were measured. Figure 1a
shows four hypothetical combinations of measurements. We
sought to score for co-occurring high or low values in the DNA
copy number data; in other words, regions that display similar
patterns of large-amplitude amplification and deletion across the
tumor set. This situation is shown in the third panel Figure 1a.
The other panels show other potential situations that may arise
when comparing two continuous measurements. To score for co-
occurring gains all negative values are set to zero (Figure 1b). To
score for co-occurring losses all positive values need to be set to
zero and the absolute values of the measurements need to be used.
We use the covariance of the two measurements to score for co-
occurring loci. This score only rewards a high value to a truly co-
occurring and co-varying pairs of measurements (Figure 1c, right
panel). However, a high covariance alone is not sufficient, since it
is possible that a high covariance occurs while at least one of the
loci never reaches a high amplitude (see Figures 1e and 1f).For this
reason we multiply the covariance score with the sum of the
individual valued in each sample. This method of scoring only
rewards a high value to a co-varying pair of measurements with a
large aberration amplitude across the tumors (Figure 1c, right
panel).
A framework for genome-wide co-occurrence scoring
The co-occurrence scores can be computed for every pair of
genomic loci (Figure 2c). By performing a two-dimensional
Gaussian kernel convolution on these scores in the co-occurrence
space we can take local neighborhood effects into account. This
operation is performed for different kernel widths in order to
capture scale dependent effects, resulting in a Convolved Co-
occurrence Matrix (CCM) as shown in Figure 2d. High values in
this matrix represent candidate co-occurring regions in the data. A
peak in the CCM can be mapped back to two specific loci, the size
of which is determined by the s parameter of the Gaussian
function used to convolve the score matrix (Figure 2e). The genes
that are located in the loci associated with a peak in the CCM are
subsequently investigated. We examined both enrichment for
Author Summary
It is generally accepted that a normal cell has to acquire
multiple mutations in order to become a malignant tumor
cell. Considerable effort has been invested in finding single
genes involved in tumor initiation and progression, but
relatively little is known about the constellations of cancer
genes that effectively collaborate in oncogenesis. In this
study we focus on the identification of co-occurring DNA
copy number alterations (i.e., gains and losses of pieces of
DNA) in a series of tumor samples. We describe an analysis
method to identify DNA copy number mutations that
specifically occur together by examining every possible
pair of positions on the genome. We analyze a dataset of
hematopoietic tumor cell lines, in which we define a
network of specific DNA copy number mutations. The
regions in this network contain several well-studied cancer
related genes. Upon further investigation we find that the
regions of DNA copy number alteration also contain large
networks of functionally related genes that have not
previously been linked to cancer formation. This might
illuminate a novel role for these recurrent DNA copy
number mutations in hematopoietic malignancies.
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functional relationships between the genes derived from the two
loci (Figure 2f). Additional details can be found in the Materials
and Methods section.
Co-occurrences in hematological cell lines
We ran our analyses on the aCGH profiles of 95 hematological
tumor cell lines analyzed on the Affymetrix Genome-Wide
Human SNP Array 6.0. See the supplemental data (Dataset S1)
for a list of the cell lines that were analyzed. The data was
generated by the Cancer Genome Project (Wellcome Trust Sanger
Institute, Hinxton, UK). We employed three scale parameters:
2Mb (s=1/3 Mb), 10Mb (s=5/3 Mb) and 20Mb (s=10/
3 Mb). In the remainder of this text we will refer to these as Scales
2, 10 and 20. These scales roughly determine the size of the
aberrant regions we expect to find. By employing a small, medium
and large scale we maximize the chance of detecting co-occurring
changes of all possible sizes. To remain conservative we limited
our primary analysis to the top 50 peaks in the Convolved Co-
occurrence Matrix (CCM) for each of the scales and each of the
comparisons (gain-gain, loss-loss, loss-gain). This resulted in 9 top-
50 lists of co-occurring regions retrieved from this dataset.
Co-occurrences involving the T-cell receptor and IgG loci
A substantial fraction of the 95 cell lines are derived from T- or
B-cell lymphomas with functionally rearranged T-cell receptor or
IgG genes. We therefore expected to identify co-occurring losses at
the T-cell receptor alpha/delta and beta/gamma loci in the T-cell
leukemias. Similarly, our method should identify co-occurring
losses at the IgG kappa, lambda and heavy chain loci in B-cell
malignancies. Because the recombination loci for both the T-cell
receptor and the IgG genes are both relatively small (in the 1Mb
Figure 1. Co-occurrence score for paired continuous variables. a. Four possibilities of pairs of hypothetical DNA copy number change
measurements are shown, for a set of samples. Each of the four hypothetical measurement pairs is plotted in scatter plot, giving each sample in the
set an x- and y-coordinate. The random pair (first panel) is a noisy pair containing no effect. The constitutive member pair (second panel) consists of
one measurement that is continuously high, paired with a measurement that varies between two noisy levels. The co-occurring signal (third panel)
consists of two noisy measurements that alternate between a high and a basal level, but show concerted change. The mutual exclusive pair (fourth
panel) also alternates between two levels but one measurement excludes the other from also reporting a high value. b. In this example we show
scoring for co-occurring gains. Therefore we set all negative values to zero. To score for loss-loss pairs we would need to set all positive value to zero
and continue using the absolute values. For loss-gain analysis we would set the positive values of the x (y) axis to zero and use the absolute values in
the x (y) direction. c. The first panel shows the resulting scores of the four pairs of measurements if only the sum of the minimum is used. The second
panel shows the score when the covariance is included.
doi:10.1371/journal.pcbi.1000631.g001
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small (2 Mb) scale analyses. Since we disregarded co-occurrences
on the same chromosome we expected to find five co-occurring
losses. Indeed, four of the five expected co-occurring losses are
present in the top 50 peaks of the Scale 2 analyses (Table 1).
Figure 3 shows two examples from the top 50 lists of co-occurring
loci. The separation of T- and B-cell lines is immediately apparent.
T-cell lines are strongly associated with losses in the T-cell receptor
loci. A large subset of B-cell lines are associated with losses in the
IgG loci. However, a subset of the B-cell lines is not associated
with any loss of these loci. In this particular subset of lines the IgG
loci seem to be gained. It is known that the IgG loci are favorite
partners for oncogenic translocations [8]. Whether this is the cause
of the amplification of these loci is not known.
Cancer gene enrichment in co-occurring loci
While the recovery of the V(D)J-related recombination loci as
co-occurring losses serves as a positive control for our analysis
approach, we are mainly interested in identifying cooperating
genes or regions that might play a role in cancer. To see whether
the locations we recover are linked to this disease, we analyzed
whether the co-occurring genomic loci are enriched for genes
known to play a role in cancer. As a reference gene set we used the
Cancer Gene Census list [9]. The results of this analysis are shown
Figure 2. Schematic overview of co-occurrence analysis. a. Overview of aCGH data. Both   y yi and   y yj are vectors of genomic grid points spanning
a chromosome arm (see Materials and Methods). The genomic grid is constructed from aCGH probe measurements, as explained in the Materials and
Methods section. b. The combinations of   y yi and   y yj are used to construct a genomic pair-wise space in which all further calculations are performed. In
this panel a schematic view of the genomic pair-wise space is shown. Each pair of genomic grid points between   y yi and   y yj is a point in this space and
each point contains two values. A pair-wise genomic matrix exists for each tumor in the data set. c. To score for co-occurrence, the minimum value of
the pairs of genomic grid points are summed over the tumors and the co-variance over tumors of all genomic grid points is calculated. This results in
two equally sized matrices which are multiplied element wise to produce the co-occurrence score matrix. This matrix is again represented in the
genomic pair-wise space (S
co-oc). d. The co-occurrence score matrix is convolved with a Gaussian matrix to find local enrichment of high co-
occurrence scores in the pair-wise space. Peaks in the convolved co-occurrence matrix are translated back to two genomic regions (in and jn) that are
annotated as being co-aberrated across the tumor set. e. For the n-th peak in the Convolved Co-occurrence Matrix (CCM) two gene sets, An and Bn,
are defined, based on a 2s window centered on the peak. f1. Using a protein-protein interaction database the interactions between gene sets
derived from a single co-occurrence peak are analyzed, producing a set of interactions (IAnBn). f2. Using the Cancer Gene Census we inspect the
resulting gene sets for presence of known tumor-suppressor genes and oncogenes.
doi:10.1371/journal.pcbi.1000631.g002
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tumor suppressor genes, and the gain-gain regions for oncogenes.
Since one expects loss of tumor suppressors and gain of oncogenes,
this is a logical result, further increasing our confidence that our
approach identifies truly relevant genomic loci.
Discovering functional relationships between
co-occurring loci
While finding enrichment for cancer genes is an encouraging
result, this does not explain the possible cooperation between two
loci. We expect that the co-occurring loss of two regions points to a
functional relationship between the constituents of the genomic loci.
A co-occurrence between two genomic regions can point to many
different kinds of interactions between the genes residing in both
regions, e.g. biochemical interactions of the protein products or
functional collaboration of two cancer genes in tumorigenesis. We
therefore decided to employ interaction data to shed further light on
the genes present in the co-occurring regions. We translated the co-
occurring pairs of genomic loci to pairs of gene sets, and we
investigated the functional relationships of their protein products
using the STRING database [10] (version 8.1). The STRING
model weighs functional associations between genes based on
several different sources of evidence, among which: biochemical
interaction, joint presence in a pathway, high-throughput interac-
tion experiments, text mining and interactions of homologs in other
species. To find a functional relationship between two co-occurring
Figure 3. Two co-occurring losses detected in the 2Mb scale analysis. Raw aCGHdataof two co-occurring losses corresponding to four genomic
loci are shown. The y-axis of the heatmapscontains the samples, ordered through standard hierarchical clustering. The x-axis containsthe probes present
in the four genomic loci, ordered by genomiclocation. The sample information bar containsthe names ofthe cell lines analyzed, the disease oforigin and
the whether the sample has a T-cell or B-cell lineage. These representations are based on the results of the analysis on the 2 Mb scale.
doi:10.1371/journal.pcbi.1000631.g003
Table 1. Occurrence of T-cell and B-cell related co-occurring
losses.
Cell lineage Loci of interaction
Rank in interaction
list (scale 2)
B-cell IgG kappa – IgG lambda 7
IgG kappa – IgG heavy chain 6
IgG lambda – IgG heavy chain 3950
T-cell TCR beta – TCR alpha/delta 1
TCR gamma – TCR alpha/delta 2
doi:10.1371/journal.pcbi.1000631.t001
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between the two gene-sets defined by our co-occurrence analysis.
To determine whether the number of observed interactions is
significant, we compared the number of direct interactions found
between genes located in the top 50 co-occurring regions to a set of
randomly chosen pairs of genomic loci. The metric we used to
determine significance is the ratio between the number of
interacting genes and the total number of genes found on the
genomic loci. A p-value for enrichment for direct interactions was
calculatedusinga two-tailed Fisher’s exact test.Results areshown in
Figure 4. As can be seen, the only analysis that resulted in an
enrichment of functional interactions is Scale 20, for all three
situations. We found no enrichment for interacting protein coding
genes on Scale 2 (not shown) and Scale 10. Since we evaluated gene
sets in a window one-third the size of the analysis-scale we may be
under-estimating the size of the co-occurring loci and the larger
Scale 20 actually captures the size of the aberrations best.
In order to keep control of the complexity, we considered in our
co-occurrence analysis only radially symmetric kernels, i.e.
Gaussian kernels withdiagonal, equal variance covariance matrices.
This implies that asymmetric co-occurring regions – where a small
locus co-occurs with a large locus – will not be optimally detected.
Since an asymmetric co-occurring region typically consists of a
series of symmetric co-occurring regions detected on a smaller scale
(just like a rectangle canbe constructed from a collectionof squares),
we set out to construct larger co-occurring regions from the results
of the smaller scales using a hierarchical clustering approach. For
details see Supplemental Figure S1.
Briefly, we collected the loci involved in the top 500 co-
occurrences of the Scale 2 analysis. This resulted in 1000 genomic
loci. For each pair of loci, we calculated the genomic distance in
base pairs. The distance between two loci on different chromosome
arms was set to a default high value (1 * 10
8). This resulted in a
100061000 distance matrix. On this distance matrix we performed
single linkage hierarchicalclustering.Theresultingdendrogramwas
cut at 1 * 10
7 bp (5 kernel widths). The resulting clusters are unique
genomic loci and were represented as nodes in a graph. Clusters
were then linked if a co-occurrence was found between individual
loci of different clusters. These links are represented as edges in a
graph. The result of the clustering analysis is shown in Figure 5.
Table 2. Enrichment for Cancer Gene Census genes in top 50 co-occurring genomic loci.
Comparison Analysis Scale (Mb) Genes present in co-occurring loci CGC
2 – Oncogenes (n – pvalue
1)C G C
2 – Suppressor (n – pvalue
1)
Loss-loss 2 198 2 - 0.56901 2 - 0.03481
10 1151 18 - 0.35721 7 - 0.0546
20 1912 31 - 0.27088 11 - 0.039637
Gain-Gain 2 221 10 - 0.00050472 0-1
10 755 17 - 0.034575 2 - 0.51641
20 1192 28 - 0.0065355 4 - 0.43198
Gain-Loss 2 86 2 - 0.1373 2 - 0.0037163
10 785 15 - 0.12887 4 - 0.15322
20 1479 31 - 0.021555 5 - 0.44561
1p-value determined by Fishers’ Exact test, p,0.05 is marked in bold script, p,0.01 is marked in bold italic script.
2Cancer Gene Census.
doi:10.1371/journal.pcbi.1000631.t002
Figure 4. Significance of finding direct interactions in co-occurring genomic loci. For two scales the top 50 co-occurring gene lists for the
gain-gain, loss-loss and loss-gain situations were compared to a random set of 100 pairs of genomic loci. For each genomic pair two gene sets were
queried for direct interactions using the STRING database. Significance was ascertained using Fisher’s exact test on the ratios between all genes and
the interacting genes for the co-occurrence gene sets versus the random gene set.
doi:10.1371/journal.pcbi.1000631.g004
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PLoS Computational Biology | www.ploscompbiol.org 6 January 2010 | Volume 6 | Issue 1 | e1000631Figure 5. Networks of co-occurring gain and loss. The networks that result from hierarchical clustering of Scale 2 results are shown in different
panels. Each panel represents either the gain-gain, loss-loss or gain-loss analysis. The resultant network is visualized using the Cytoscape software
package (www.cytoscape.org). Edge thickness scales according to the number of co-occurrence links found between the two genomic loci. The size
of the nodes is proportional to the highest rank found among the different individual loci that constitute a node. If only one genomic location is
present in a node, i.e. this location did not cluster with any other locations, it is colored gray. The cancer gene enrichment among all genes mapping
to the locations described by the nodes is shown in the top right hand corner. P-values are determined by Fisher’s Exact test. The functional
interaction enrichment of all genes between nodes that are linked with an edge is represented in the lower right hand corner of each panel. P-values
are determined using Fishers’ Exact test, with randomly generated pairs of loci representing the null hypothesis.
doi:10.1371/journal.pcbi.1000631.g005
Co-Occurrence in Tumor DNA Copy Number Aberrations
PLoS Computational Biology | www.ploscompbiol.org 7 January 2010 | Volume 6 | Issue 1 | e1000631A network view of co-occurring copy number changes
As can be seen in Figure 5 we were able to construct a network
of co-occurring copy number changes for the gain-gain, loss-loss
and gain-loss situations. As expected, the gain-gain and loss-loss
networks show enrichment for oncogenes and tumor suppressor
genes, respectively. The gain-loss network only shows enrichment
for tumor suppressors. The percentage of genes involved in
functional interactions between the nodes that are linked in the
graph vastly exceeds the functional interaction enrichment found
in the single scale 20 Mb analyses. At least 11% of the genes
present in the genomic locations - represented by the nodes in the
graphs - have high confidence (.0.9) annotated functional
interactions along the edges as revealed by STRING analysis.
The thickness of the edges in the graphs shown in Figure 5 indicates
how often a co-occurrence was found in the top 500 of the Scale 2
analysis. Several edges were strongly supported by co-occurrences in
the top 500. These strongly supported edges were always associated
with loci that were ranked high in the co-occurrence list (as indicated
by node size). The nodes that are associated with these highly
represented edges seem to form an important subgraph. To reveal
these subgraphs, we removed all edges supported by less than 5% of
the top 500 co-occurrences. For brevity and simplicity we only
consider the gain-gain and loss-loss networks. This resulted in the two
core networks shown in Figures 6 and 7.
The gain-gain core network
Theedgethicknessofthegain-gaincorenetworkshowninFigure6
represents the number of functional interactions found using the
STRING database between genes that map within the loci described
by the nodes. To determine the common denominator among the
interacting genes, we employed Ingenuity Pathway Analysis (IPA;
Ingenuity Systems) to perform a functional enrichment analysis on all
genes residing within the gain-gain core network. This revealed
strong enrichment for processes involved in cancer (Figure 6b). From
Figure 6a it is immediately apparent that most of the functional
interactions are found between 1q and 7p/q. If we remove the 1q
node from the entire network described in Figure 5 the enrichment
for functional interaction drops dramatically (Figure 6c). Therefore,
we hypothesize that the co-occurring gainbetween 1q and 7p/q isthe
most important effect in the gain-gain analysis in this dataset. This is
strengthened by the fact that almost all known oncogenes within the
entire network map to 1q, 7p or 7q (Figure 6a). The well-studied
canonical oncogene MYCmapsto8q andisnotadetermininghub in
the gene interaction network as constructed by STRING.
Figure 6. The gain-gain core network. a. The reduced core network for the gain-gain analysis obtained by pruning all edges with less than 5%
support in the top 500 list of the Scale 2 analysis. Edge thickness and label represent the number of functional interactions between genes associated
with the nodes being connected based on the STRING database. The oncogenes as defined by the Cancer Gene Census that map within the regions
defined by the nodes are shown in rectangular insets. b. Representation of the 10 most enriched Ingenuity terms associated with the entire collection
of genes in the core network that have a STRING interaction along the edges. The x-axis shows the 2log transformed p value, corrected by the
Benjamini Hochberg procedure as implemented in the Ingenuity software. c. Functional interaction enrichment is shown as a bar graph, which
represent the ratio of interacting genes with respect to the total number of genes. P-values are determined using a Fishers’ Exact test with randomly
selected pairs of loci representing the null hypothesis.
doi:10.1371/journal.pcbi.1000631.g006
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The loss-loss core network is shown schematically in Figure 7a.
A loss of approximately 18 megabases on chromosome 17p
appears to be a central hub, which is co-lost with several other
genomic loci. These loci show a very high enrichment of genes
that interact with 17p, and of the six loci, four contain multiple
known tumor suppressor genes. A functional enrichment analysis
of all genes residing on loci co-lost with 17p, reveals many cancer-
related processes (Figure 7b), suggesting that the interacting genes
are most likely also the cancer-relevant genes. If we remove 17p
from the original network we see a large decrease in the
percentage of genes involved in functional interactions (Figure 7c)
confirming the importance of 17p in the loss-loss network.
The co-occurring losses involving 17p might target
non-canonical cancer genes
One of the most intensively studied cancer genes, TP53, resides
in the 17p locus. Furthermore, the canonical cancer gene RB1 and
the CDKN2A/B locus are present in two of its co-lost regions. Since
these are well known tumor suppressors, and therefore the subject
Figure 7. The loss-loss core network. a. The reduced core network for the loss-loss analysis determined by pruning all edges with less than 5%
support in the top 500 list of the Scale 2 analysis. Edge thickness and label represent the number of functional interactions between genes associated
with the nodes being connected based on the STRING database. The tumor suppressor genes as defined by the Cancer Gene Census that map within
the regions defined by the nodes are shown in rectangular insets. b. Representation of the 10 most enriched Ingenuity terms associated with the
entire collection of genes that have a STRING interaction between the 17p region and 9p, 9q, 13q, 16q or 22q as determined by the Ingenuity
software. The x-axis shows the 2log transformed p value, corrected by the Benjamini Hochberg procedure as implemented in the Ingenuity software.
c. Functional interaction enrichment is shown as a bar graph, which represent the ratio of interacting genes with respect to the total number of
genes. P-values are determined using a Fishers’ Exact test with randomly selected pairs of loci representing the null hypothesis. d. A functional
interaction network around the nuclear co-repressor NCOR1 (also known as TRAC1) is shown. This network is a part of the network of interactors
derived from the 17p interacting regions after removal of the canonical cancer genes TP53, RB1, CDKN2A and CDKN2B from the analysis. e. Illustration
of the retroviral insertions mapped near CBFA2T3, recovered in a large screen of MuLV retroviral mutagenesis [11]. Insertions are shown as triangles.
Blue triangles indicate insertions in the direction of transcription (plus), red triangles indicate insertions in the anti-transcription direction (minus).
Insertions linked by dashed boxes are bi-allelic integrations recovered from the same tumor.
doi:10.1371/journal.pcbi.1000631.g007
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the functional relationships in our analysis. To test this hypothesis,
we excluded these four genes and repeated the interaction analysis
of the core network. As can be seen in Figure 7c, the enrichment is
only slightly lower without the canonical genes, suggesting that the
functional relationship between the co-occurring losses on 17p and
the other loci are driven by other genes.
We investigated the remaining 113 interactors for any
interesting interactions that might be a target of this collection of
co-occurring losses. Within the total network of interactors we
found a sub-network centered on the nuclear co-repressor NCOR1
(TRAC1) (Figure 7d). This interaction network included – besides
NCOR1 – the peroxisome proliferator-activated receptor alpha
(PPARA), the MAPK pathway suppressor GPS2, the nuclear co-
activator (and known tumor-suppressor) p300 and a gene of
unknown function, CBFA2T3. All interactions found are based on
physical binding and co-occurrence in Pubmed abstracts.
Combining co-occurrence data with insertional
mutagenesis data
To see whether we could find more information regarding the
putative tumor suppressor function of the different interactors, we
tested if we could corroborate our findings with data from a large
retroviral insertional mutagenesis (IM) screen where hematopoietic
tumors were induced through Murine Leukemia virus (MuLV)
infection of wild-type mice or Trp53 or p19-ARF deficient mice
[11]. An illustration of the retroviral insertions sites near Cbfa2t3 is
shown in Figure 7d. Although Cbfa2t3 was not flagged as a
common integration site, several viral integrations near this gene
were found. Remarkably, two individual tumors harbored a bi-
allelic integration near the transcription start site of Cbfa2t3,
suggesting functional inactivation of this candidate tumor
suppressor gene. Indeed, bi-allelic integration is thought to be a
hallmark of tumor suppressor genes in IM screens [12].
Given that we find this sub-network of interactors in a co-
occurring network of DNA copy number losses and the recovery of
inactivating insertions in a retroviral IM screen, we conclude that
this network might be a putative tumor suppressor network.
Discussion
In this study we present a genome-wide analysis for finding
collaborating DNA copy number changes on different chromo-
somes. Using our 2D kernel convolution framework we can score
and find co-occurring DNA copy number changes in a high
quality, high resolution aCGH dataset. Using a dataset of
hematological cell lines we are able to recover DNA copy number
alterations specific to the cell lineage of the samples. Furthermore
we uncover cancer-related networks of co-occurring DNA copy
number changes.
Previous work on co-occurring copy number changes
Several studies have investigated concerted copy number
changes in aCGH data. In studies on lung cancer [13] and
ovarian cancer [14] the authors performed a post-hoc co-
occurrence analysis on genomic locations that were found to be
significantly altered in a one-dimensional analysis. A more
integrated effort to analyze relations between CNAs in brain
cancer was published recently [15]. Although this study scores
systematically for co-aberration, it is limited in resolution as it
employs cytobands as the genomic unit within which aberrations
are scored. Cytobands are relatively arbitrarily determined entities
and are quite heterogeneous in size. Furthermore this approach is
dependant on converting the continuous-valued copy number data
to discrete copy number calls. This results in loss of important
information since it removes the possibility of weighting the
intensity of a CNA. In contrast, our approach is able to correct for
unequal probe distances, enabling us to perform our analysis on a
very high (20 kbp) resolution. In addition, our scoring method not
only incorporates the sign of the copy number change, but also its
intensity and the concomitant CNAs within the immediate
genomic neighborhood.
Determining significance of co-occurrences
The output of our analysis does not include a measure of
significance. Constructing a background distribution based on
permutations of the DNA copy number data would mean re-
running our analysis thousands of times, a task which remains
computationally infeasible at this stage. Furthermore, the multiple-
testing problem would have to be properly addressed, given that
the number of tests is the square of the number of grid points in
the 2D space. Due to the complexity of the analysis procedure
(minimum operation and kernel smoothing) the definition of an
analytical null distribution has remained elusive. Therefore, we
have chosen to work with top n results, residing in the extremes of
the results distribution, thus minimizing the chance of including
false positives. The top n lists allowed us to generate workable
results which we have validated extensively with other sources of
evidence.
Analytical challenges
While we were able to use a distributed computing solution for
our analysis, we were fortunate to have the required computa-
tional architecture at our disposal. Since the problem basically
consists of repeating the same action many times it could be well-
suited to software optimization or a hardware based solution
where the most time-consuming actions are handled by a
dedicated processing unit.
When looking for areas in the 2D pair-wise space highly
enriched for co-occurrence scores we convolve this space with a
2D-Gaussian kernel. The sigma parameter of this function is a
representation of the size of the aberrations we expect to recover.
Currently we make the implicit assumption that the co-occurring
aberrations have the same size by using a symmetric kernel for the
convolution. This could be relieved by allowing for an asymmet-
rical (ellipsoid) Gaussian kernel for all combinations of scales used.
Clearly, this comes at the cost of increased computational
complexity. Here we resolve this issue by concatenation of the
results obtained in a small scale. In this way we can recover co-
occurring losses of different sizes that give a better enrichment for
functional interactions when combined with the single peaks
obtained in a higher scale analysis.
Gene dosage effects on a large number of genes
In our analysis of a set of cell lines derived from hematological
malignancies we found enrichment of cancer related genes and
functional interactions in co-occurring DNA copy number
changes. Our results suggest that tumorigenesis requires elimina-
tion of multiple gatekeeper genes and gain of multiple oncogenes
as demonstrated by the presence of many functional interactions
between the loci in the gain-gain and loss-loss core networks.
Haploinsufficiency is a well known characteristic of several
tumor suppressor genes, where simple reduction of gene dosage by
loss of gene copies at the DNA level can already promote
oncogenic transformation [16]. It is conceivable that changes in
gene dosage of multiple interconnected genes involved in cancer-
related processes such as cell cycle, DNA repair and signaling can
also weaken a cells defense against uncontrolled cell proliferation.
Co-Occurrence in Tumor DNA Copy Number Aberrations
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such as the ones identified in this study, might effectively sensitize
cells to become tumorigenic.
17p as a central player in co-occurring losses
We show that the 17p loss and its co-lost regions are highly
enriched for functional relationships, which are not fully explained
by the presence of the TP53 gene, often thought to be the single
target of this deletion [17–19]. Although TP53 is no doubt an
important target of the DNA copy number loss, our analysis
indicates that the concomitant loss of other genes near TP53,a s
well as co-occurring losses on the other genomic loci may together
account for the full tumorigenic effect.
Loss of the loci on 17p, 9p, 9q, 13q, 16q and 22q has been
reported previously for several types of hematological malignan-
cies represented in our dataset [20–23]. The picture that emerges
from this analysis of collaborative aberrations is that many of the
reported losses collaborate with the frequently occurring 17p loss
as a central hub. We don’t recover co-occurring losses among the
spoke loci in the core network. This could suggest that the non-17p
regions form subsets of co-occurring losses with 17p, whose
interconnections themselves do not occur frequently enough in the
top 500 co-occurring losses we investigated.
NCOR1 and its interactors
Not all of the gene-gene interactions defined by the 17p network
involve the well-known canonical cancer genes TP53, RB1 and
CDKN2A (INK4a/ARF). We found one sub-network of genes
around NCOR1 which might be an example of other tumor
suppressor genes that are affected by the concerted loss of these
genomic loci.
The hub of this interaction network, NCOR1, is a well-known
transcriptional co-repressor that associates in a ligand-independent
manner with nuclear receptors [24]. It is responsible, together with
the closely related factor SMRT, for recruitment of HDAC
proteins to the DNA to induce transcriptional silencing. Its role in
cancer is not well-established. NCOR1 null mice die in early
embryogenesis [25]. A dominant-negative mutant of NCOR1 is
known to increase proliferation in hepatocytes [26] and more
recently it has been shown that NCOR1 decreases AKT
phosphorylation, thus countering its pro-survival signal [27]. It
would seem that specific loss - or at least decrease in gene dosage
of NCOR1 - might increase proliferation and promote survival.
All interactions between NCOR1 and its partner genes (PPARA,
GPS2 and CBFA2T3) have been based on co-occurrence in
PubMed abstract and true physical binding [28–31]. CBFA2T3 is a
close relative of ETO, which is a target of the recurrent AML1-
ETO translocation that occurs in acute myeloid leukemia. It has
been shown that the fusion gene AML1-ETO actually interferes
with the CBFA2T3-NCOR1 interaction, and that its oncogenic
effect derives from that inhibition [31]. In a retroviral insertional
mutagenesis screen in mice, Cbfa2t3 is recurrently targeted by bi-
allelic retroviral integrations, which are predicted to cause
functional inactivation of Cbfa2t3 [11]. PPARA is a member of
the Peroxisome proliferator-activated receptors, and has been
implicated in hepatocellular carcinoma development in rodents
[32]. Since other members of this family, such as PPARG, exhibit a
tumor suppressor-like phenotype, it is possible that PPARA can act
as a tumor suppressor in hematological malignancies. GPS2 is a
known suppressor of JNK signaling [33], which is one of the
constituents of the MAP kinase signaling pathway. Deregulation of
this pathway is a well-known phenomenon in cancer [34]. Taken
together with the association between NCOR1 and the known
tumor suppressor p300, our data suggest a selective advantage for
loss of multiple constituents that interact with NCOR1 since they all
may have tumor suppressor-like activities.
Many studies focus on a single hematological malignancy in
which a single combination of aberrations might be important
[19,35,36]. Since we examine a large panel of samples derived
from many different hematological malignancies, our results might
not specifically apply to any single type of lymphoma or leukemia.
They might hint at more general processes that are important for
the tumors to arise and maintain themselves. However, one should
not forget that this analysis is based on a panel of cell lines, which
may have adapted to in vitro tissue culture conditions by acquiring
additional aberrations that are rarely found in real tumors in
patients. Furthermore, given the fact that we examine copy
number changes it might be worthwhile to analyze a highly
genomically unstable tumor type, such as BRCA1/2-related breast
cancer.
Conclusions
We have developed a method for genome-wide analysis of
collaborating DNA copy number changes and their corresponding
networks. Using this approach we have identified a loss-loss
network centered around a region on human chromosome 17p.
This network is highly enriched for functional relationships and
hints at a more complex system of tumor suppression in which
many different genes are affected simultaneously to induce cancer.
We show one example of a sub-network around the nuclear co-
repressor NCOR1 that may be a novel network of tumor suppressor
genes that are affected by the observed co-occurring losses. The
observation that DNA copy number changes may affect gene
dosage of larger numbers of cancer-relevant genes deviates from
the classical view where mutations in a few (5–7) cancer genes lead
to tumor development. Our data support the notion of cancer-
related networks or pathways, where multiple collaborating genes
are deregulated simultaneously to induce oncogenesis. Such a
network view of oncogenesis is an important step towards
developing effective drug targets because it increases the number
of potential targets. However, this view also implies that multiple
molecules need to be targeted simultaneously in order to achieve
optimal therapy response and to reduce the risk of therapy
resistance.
Materials and Methods
Transformation of probe-measurements to genomic grid
Datasets consisting of array-based copy number measurements
are continuously increasing in size. If probe level interactions are
evaluated, the analysis space is of dimensionality N2 for N probes
on the genome. As a result, the analysis time and memory usage
will also increase quadratically with the number of probes. Instead
of a grid positioned at the genomic positions of the probes, we
employ an equally spaced genomic grid as a basis for all
subsequent steps. The distance between grid-points is a user-
defined variable, and will determine the finest resolution of the
outcome and computational efficiency. We have performed all
analyses using a genomic grid with a grid spacing of 20 Kb. Given
a genome of G base pairs and a grid spacing of D, this results in
NG grid positions, with NG~tG=Ds, where tzs represents the
integer part of the real number, z. The grid positions can be
represented in the following row vector:   x x~fxkjk~1,2,:::,Ngg,
where xk~kD.
Let the aCGH profile of the tth tumor be represented by the
following row vector of probe measurements:   a at~fat,kj k~1,2,:::,pg,
with p being the number probes. Let the midpositions of the probes be
located at  z z~fzkjk~1,2,:::,pg. To employ the genomic grid we need
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the grid points. We achieve this by performing,for thekth grid position,
xk, a kernel-weighted regression of all probe values situated in the
range ½xk{D;xkzD ~½D(k{1);D(kz1) , employing a triangular
kernel centered at xk, with maximal amplitude of 1 and width of 2 D.
More specifically, the interpolated copy number aberration at the kth
grid position is given by:
bt,k~
P
j[Jk
at,k:(1{
xk{zj
       
D
)
P
j[Jk
(1{
xk{zj
       
D
)
ð1Þ
Here the set Jk is the set of probe positions such that Jk~
fjj xk{zj
       ƒD, j~1...pg. The interpolated copy number profile
of the tth tumor is represented by the row vector:   b bt~
fbt,kj k~1,2,:::,Ngg. The complete dataset of T tumors is re-
fopresented by the matrix B~f  b b1,  b b2,:::,  b bTg, where the probe values
of the tth tumor constitute the tth row of matrix B.
Separating gains and losses
Negative and positive log2 values respectively denote loss or
gain of DNA in the test sample versus the reference sample. We
regard both situations separately, which prevents the negative and
positive values cancelling each other through summation later in
the algorithm. We separate gains and losses by only retaining grid
positions with positive values for the gains or negative values for
the losses. The absolute values of the separated matrices are then
used in the downstream steps. The remaining grid positions are set
to zero. More specifically, the gains matrix, Bz is given by
Bz~fbz
t,kjt~1,2,:::,T, k~1,2,:::,Ngg, with
bz
t,k~
bt,k, if bt,kw0
0 otherwise
 
ð2Þ
Similarly, the loss matrix, B{ is given by B{~
fb{
t,kjt~1,2,:::,T, k~1,2,:::,Ngg with
b{
t,k~
jbt,kj, if jbt,kjv0
0 otherwise
 
ð3Þ
Because we treat gains and losses separatelywe have four different co-
occurrence situations to be considered given two loci on the genomic
grid: i) gain/gain, ii) gain/loss, iii) loss/loss and iv) loss/gain. So, when
evaluating the co-occurrence of loci i and j, we will evaluate the
behavior of i) columns Bz
.,i and Bz
.,j for gain/gain; ii) columns Bz
.,i
and B{
.,j for gain/loss; iii) columns B{
.,i and B{
.,j for loss/loss and iv)
columns B{
.,i and Bz
.,j for loss/gain. (Here X.,i is the ith column of
matrix X). All subsequently described steps will be performed for
these four situations separately, where   y yi~fyt,ijt~1,2,:::,Tg and
  y yj~fyt,jjt~1,2,:::,Tg will be employed as shorthand for the
abovementioned column vectors of interpolated copy number values
associated with genomic grid positions i and j,r e s p e c t i v e l y .
Co-occurrence score
The first component of the co-occurrence score is the
continuous variant of the AND Boolean logic function: the
minimum operation. For two grid points, i and j, the sum across
all tumors of the minimal probe value per tumor at i and j, smin
i,j ,i s
calculated as follows:
smin
i,j ~
X T
t~1
min(yt,i,yt,j) ð4Þ
These values are aggregated in a matrix, S
min~
fsmin
i,j ji,j~1,2,:::,Ngg. If we only use the minimum as a scoring
function, those grid positions that are ubiquitously aberrated will
always receive a high score, regardless of the aberration pattern in
the other grid position. Two regions that are aberrated
ubiquitously in all tumors are undoubtly important to the tumor
but they are not necessarily functionally related. They might be a
hallmark of the particular disease under study, but show no direct
functional interaction. To prevent these ubiquitously aberrated
regions from dominating the analysis and to detect those regions
that represent functional co-occurrences, we weigh the minimum
score computed above with the covariance of the interpolated
probe values at the two grid positions i and j,
scov
i,j ~cov(  y yi,  y yj)~
1
T
X T
t~1
(yt,i{mi)(yt,j{mj) ð5Þ
where mi and mj are the expected values of the probe values
at grid position i and j across tumors, respectively (i.e. mi~
1
T
X T
t~1
yt,i and mj~
1
T
X T
t~1
yt,j). These values are aggregated in a
matrix, S
cov~fscov
i,j ji,j~1,2,:::,Ngg. We combine both the
minimum matrix and the co-variance matrix by element-wise
multiplication to form the co-occurrence score matrix, S
co-oc~
fsco{oc
i,j ji,j~1,2,:::,Ngg,w i t h
sco{oc
i,j ~smin
i,j :scov
i,j ð6Þ
Kernel convolution
Since we believe the co-occurrence score to be a smooth
variable, and since neighboring co-occurrence values can therefore
be employed to reduce the noise locally, we convolve the co-
occurrence score matrix with an isotropic 2D Gaussian kernel
function. In practice this implies sampling the 2D Gaussian kernel
function on a square grid consisting of M6M genomic grid
positions and then performing the convolution of this sampled
kernel function with the co-occurrence score matrix. The sampled
isotropic 2D Gaussian function is defined as G~fgi,jji,j~
½{M,{(M{1),:::,{1,0,1,:::,(M{1),M g, with
gi,j~e
{ Di ðÞ 2z Dj ðÞ 2 ½ 
2s2 ð7Þ
The standard deviation of the isotropic Gaussian, s, determines
the scale of the analysis. Since the Gaussian quickly decays we set
M~t
3s
D
s, allowing contributions from +3s, convolving with a
finite kernel with minimal loss in accuracy. The scale of an analysis
is therefore defined as 6s. The scales employed in this study are:
2M b ( s=1/3 Mb), 10Mb (s=5/3 Mb) and 20Mb (s=10/
3 Mb). Before the convolution step, we pad the co-occurrence
matrix by mirroring the true data at each chromosome boundary
and each centromere. By convolving the appropriately padded co-
occurrence score matrix and the sampled 2D Gaussian function
the Convolved Co-occurrence Matrix (CCM) is obtained:
C~G   S
co{oc ð8Þ
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ci,j~
X M
l~{M
X M
m~{M
gl,msco{oc
izl,jzm ð9Þ
This matrix is a representation of the amount of co-occurrence
between two locations on the genome. We calculate a CCM-
matrix for each possible combination of chromosome-arms and for
each of the four combinations of gains and losses listed above.
Distributed computing
With 39 unique chromosome arms in the human genome
(disregarding the p-arms of the acrocentric chromosomes and the
sex chromosomes), three different scales and 4 triangular pair-wise
matrices to evaluate (loss-loss, gain-gain, gain-loss and loss-gain)
we compute 8892 different CCMs. To solve this problem
computationally we used a large distributed computing cluster.
Our choice of resolution of the genomic grid was bounded by the
memory present on the nodes. We set D to 20000 base pairs,
which is the lowest value still allowing the largest chromosome-
arm pair to be successfully computed on one computing node.
Downstream analyses
For each CCM we determine the top N peaks for each
combination of gains and losses. The n
th peak represents two co-
occurring loci, in and jn, and the location of the peak is defined by
two co-ordinates on the genomic grid: (xin;xjn). For each locus, we
define a region of interest of size 2s centered on xin and xjn,
respectively. We define this small region of interest to only select
regions that are very near to the actual peak. To investigate the co-
occurrence for functional relationships, we extract, for each of the
co-occurring loci, the genes present in the regions of interest. More
specifically, we define, for loci in and jn, the associated gene sets An
and Bn, where
An~fgjxin{sƒqgƒxinzs,Vggð 10Þ
and
Bn~fgjxjn{sƒqgƒxjnzs,Vggð 11Þ
Where qg is the position of gene g, which we chose to be the mid-
position of the gene. The genesets were established by a BioMart
query from the Ensembl database. We restricted ourselves to the
bio type ‘protein_coding’.
Cancer Gene Census (CGC) enrichment
The list of CGC genes was obtained from the CGC website
(http://www.sanger.ac.uk/genetics/CGP/Census/). The refer-
ence list of all genes was retrieved from the Ensembl website,
with a filter to keep only genes with bio-type=‘protein_coding’.
This left 18840 genes. All CGC genes that could not be mapped
back to the reference gene set were excluded. The CGC genes that
were annotated as ‘recessive’ were used as the tumor-suppressor
genes and ‘dominant’ as oncogenes. Enrichment for all CGC
genes, the tumor-suppressor subgroup and the oncogene subgroup
in the gene sets determined by the co-occurrence analysis was
calculated using a Fisher’s exact test.
Analysis of functional relationships
The set of pairs of interacting genes which are such that one
gene is associated with locus in and the other gene of the pair with
locus jn is then defined as
IAnBn~ffgk,glgjgk[An, gl[Bn, IC(gk,gl)w0:9gð 12Þ
Where IC(gk,gl) represents the confidence of interaction, according
to the STRING database, between genes gk and gl.W et h e n
determine all gene lists of interactors for the top N peaks of a given
co-occurrence analysis, i.e.:
IN~
[ N
n~1
IAnBn ð13Þ
For each of the top N co-occurring loci, we also determine the total
number of genes in the regions of interest of those loci. So, for loci in
and jn we define the set:
GAnBn~ffgk,glgjgk[An,gl[Bngð 14Þ
The total number of genes associated with the top N co-occurring
loci is then given by
GN~
[ N
n~1
(GAnBn) ð15Þ
The interaction ratio, RN
I , is then defined as
RN
I ~
jINj
jGNj
ð16Þ
where a jj denotes the cardinality of set a. As a control we randomly
pick size-matched locations for all co-occurring regions (in,jn) in the
top N and repeat the process for recovering interactions. For 100
randomly chosen co-occurring regions we calculate the resulting
RRAND
I . A Fisher’s exact test is then used to asses the significance of
enrichment of RN
I versus RRAND
I .
Hierarchical clustering of co-occurrence loci
For all pairs of co-occurring loci, (in,jn), present in the top N of
an analysis,
LN~f(in,jn)jn~1,2,:::Ng
let the set of loci representing the first and second member of the
co-occurrence locus be defined as
LN
I ~finjn~1,2,:::Ng
and
LN
J ~fjnjn~1,2,:::Ng
respectively. Given that the pairs of genomic locations corre-
sponding to the top N co-occurring loci are given by
XN~f(xin;xjn)jn~1,2,:::,Ng
we define the set of genomic locations loci involved in co-
occurrences as
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0
N~fxkjk[(LN
I |LN
J )g
For each possible pair of locations (m,n) in X
0
N the genomic
distance is aggregated in matrix D:
D~fdm,njm,n~½1,2,:::,2N g ð18Þ
Where dm,n is defined as:
dm,n~
xm{xn jj ,if xm and xn areonthesamechromosomearm
1:108 otherwise
 
ð19Þ
We perform hierarchical clustering on matrix D using single
linkage hierarchical clustering. Leaf nodes are assigned to clusters
using a distance cutoff of 10
7 bp (10Mb). Clusters are represented
as nodes in a graph. Edges between nodes are drawn if any co-
occurrence relationship is found between loci present in the nodes.
Data description
The case we subjected to analysis was a dataset containing 105
cell-lines derived from hematological origin. The aCGH mea-
surements were done on 1.8 million probe Affymetrix SNP 6.0
arrays. After data pre-processing we were left with 95 samples.
These cell lines are a subset of the Cancer Genome Project cancer
cell line project (http://www.sanger.ac.uk/genetics/CGP/CellLines/).
A list of the cell lines included in this dataset can be found in
Dataset S1.
Supporting Information
Figure S1 Hierarchical clustering of small scale CCM peaks. a.
All peaks present in the top 500 that report a co-occurrence
between these chromosome arms can be represented as a table of
1000 genomic loci, with 500 pairwise co-occurrence relationships.
b. The 1000 genomic loci are individually clustered based on their
genomic distance. The distance between two loci is the absolute
difference in basepairs if both are mapped to the same
chromosome arm and a high constant value if not. Single linkage
is used to grow a dendrogram from these distances. Clusters of
genomic loci are defined by aggregating all children under a
certain set cutoff distance, 10Mb in this case. c. The clusters
defined in b. are represented as nodes in a network. Edges are
drawn between nodes if a co-occurrence relationship exists
between any genomic loci assigned to the clusters.
Found at: doi:10.1371/journal.pcbi.1000631.s001 (1.14 MB EPS)
Dataset S1 This file contains information about the cell lines
used in this study.
Found at: doi:10.1371/journal.pcbi.1000631.s002 (0.03 MB XLS)
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